(Q43735013)

26 November 2017

Clinical experiences with low-molecular weight heparins in pediatric patients (English)

1 reference

26 November 2017

Hofmann S

1

1 reference

26 November 2017

Knoefler R

2

1 reference

26 November 2017

Lorenz N

3

1 reference

26 November 2017

Siegert G

4

1 reference

26 November 2017

Wendisch J

5

1 reference

26 November 2017

Mueller D

6

1 reference

26 November 2017

Taut-Sack H

7

1 reference

26 November 2017

Dinger J

8

1 reference

26 November 2017

Kabus M

9

1 reference

26 November 2017

language of work or name

1 reference

1 September 2001

1 reference

26 November 2017

1 reference

26 November 2017

103

1 reference

26 November 2017

345-353

1 reference

26 November 2017

5

1 reference

Indications and drugs for anticoagulation therapy in children

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

The comparison of the pharmacokinetics of a low molecular weight heparin in the newborn and adult pig.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

Low molecular weight heparins

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

Anticoagulation therapy in pediatric patients with sinovenous thrombosis: a cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

The use of low molecular weight heparin in pediatric patients: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

Long-term anticoagulation of outpatients with adverse events to oral anticoagulants using low-molecular-weight heparin.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

Prevention of hepatic artery thrombosis in pediatric liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

Heparin-induced thrombocytopenia in children

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

Routine Heparin Therapy Inhibits Adrenal Aldosterone Production*

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

Heparin-induced thrombocytopenia in a child

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

Anticoagulant effects of heparin in neonatal plasma.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

Antithrombotic therapy in children

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

Heparin therapy in pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

Low molecular weight heparin for anticoagulation during haemodialysis in children--a preliminary study.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

Thrombotic complications of heparin therapy: including six cases of heparin--induced skin necrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900335-8

7 January 2021

10.1016/S0049-3848(01)00335-8

Identifiers

DOI

1 reference

26 November 2017

1 reference